Award
NIH Reporter #4R01CA292654-03
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
Recipient
Not specified
Award Amount
$1,813,962.00
Ceiling
$1,813,962.00
Awarded
August 11, 2026
Identifier
4R01CA292654-03
A clinical trial funded by the National Cancer Institute to study the synthetic lethality interaction between CD105 and androgen receptor signaling in castration-resistant prostate cancer patients, aiming to improve treatment strategies using nanotechnology for molecular analysis.
Description
This project involves a clinical trial to evaluate the combination of apalutamide and CD105 inhibition in prostate cancer patients resistant to androgen receptor signaling inhibitors. The study leverages nanotechnology platforms for molecular analysis and aims to understand mechanisms of resistance and identify patient selection criteria.